However, as trastuzumab, with or without pertuzumab, is increasingly used in the (neo)adjuvant setting, HER2-positive breast cancer patients who experience disease progression after (neo)adjuvant trastuzumab and/or pertuzumab require special attention. Here, ERBB2 is linked to breast cancer.